Consensus likely to lower ‘22e adj. EBITDA by 2-5% The top line came in slightly above Factset consensus expectations, but so did adj. opex ex. D&A. In total, we expect cons to slightly lower ‘22e adj. EBITDA by low to mid-single digits. In addition, we note that Physitrack reiterates its target of exceeding 30% organic growth annually, and an EBITDA margin of 40-45% in the medium term.
YTD performance and conf. call details The share is -34% YTD (while OMXSPI is -24%). A webcast will be held at 10.00 (CET). In addition, we look forward hearing more at the conference call starting 10.00 CEST. Link to webcast: https://tv.streamfabriken.com/physitrack-group-q2-2022.
Läs mer på ABG Sundal Collier
Aktuellt
SENASTE
